Recent News

• 11.03.2025 - Immutep Receives A$4.6 million R&D Tax Incentive from French Government
• 10.29.2025 - Immutep Quarterly Activities Report Q1 FY26
• 10.20.2025 - Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
• 10.20.2025 - Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer
• 10.13.2025 - Immutep Announces Successful Completion of FDA Project Optimus Requirements
• 10.09.2025 - Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
• 09.22.2025 - Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti

Recent Filings

• 10.30.2025 - EX-99.1 EX-99.1
• 10.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.24.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 10.21.2025 - EX-99.1 EX-99.1
• 10.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.21.2025 - EX-99.1 EX-99.1
• 10.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.14.2025 - EX-99.1 EX-99.1
• 10.09.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]